CONSORT diagram: NSABP Protocols B-30, B-31, B-34, and B-38. BC

Landmark trials in breast cancer.pptx

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial, Breast Cancer Research

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Frontiers Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment

Postoperative dose-dense sequential versus concomitant

A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study - Clinical Breast Cancer

Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial, Breast Cancer Research

View of Abemaciclib (Verzenio) Canadian Journal of Health Technologies